Clinical trial to assess the safety of a coronavirus vaccine in healthy men and wome

Phase 1

Completed

• Conditions: COVID-19 (SARS-CoV-2 infection); Infections and Infestations

• Registration Number: ISRCTN17072692
• Lead Sponsor: Imperial College London

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35043093/ (added 20/01/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36684396/ (added 24/01/2023) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36194628/ Sub-study results (added 09/07/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-04
• Study Completion: 2021-07-31
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

1. Healthy adults from the following age ranges:
1.1. For the dose escalation and evaluation, aged 18- 45 years on the day of screening
1.2. For the expanded safety evaluation, aged 18-75 years on the day of screening
2. At a similar risk of acquiring SARS-CoV2 infection to the general population
3. Willing and able to provide written informed consent
4. If female and of childbearing potential and not sterilised, willing to use a highly effective method of contraception from screening until 18 weeks after the last injection
5. If male and not sterilised, willing to avoid impregnating female partners from screening until 18 weeks after last injection
6. Willing to avoid all other vaccines 4 weeks after the first injection through to 4 weeks after the second injection
7. Willing and able to comply with visit schedule, complete online diaries and provide samples
8. Willing to grant authorised persons access to his/her trial-related medical record and GP records either directly or indirectly

Exclusion Criteria

1. Pregnant or lactating
2. Presence of active systemic disease or pre-exisiting conditions that require investigation or a change to treatment that in the opinion of the investigator may compromise the volunteer’s safety, preclude vaccination or compromise interpretation of the immune response to vaccine
3. History of COVID-19 infection
4. History of severe or multiple allergies to drugs or pharmaceutical agents
5. History of severe local or general reaction to vaccination defined as:
5.1. Local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours
5.2. General: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
6. Ever received an experimental vaccine against COVID-19
7. Receipt of any immunosuppressive agents within 18 weeks of screening by any route other than topical
8. Detection of antibodies to hepatitis C
9. Detection of antibodies to HIV
10. Grade 1 and above abnormalities in routine laboratory parameters (see Table 4) using the FDA toxicity table Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (https://www.fda.gov/media/73679/download)
11. Participating in another clinical trial with an investigational drug or device, or treated with an investigational drug within 28 days of screening
12. Has received an immunisation within 28 days of screening

Study & Design

• Study Type: Interventional
• Study Design: Not specified